Engflag

Calcitab

Quick links to important sections

Calcitab

Selected form

Calcitab_EN

Method of action: Antacid, Antiulcer, Compensating Calcium Deficiency, Mineral, Mineral Supplements

Treatment option: Allergic Reactions, Pregnancy, Osteomalacia, Osteoporosis, Renal Failure, Rickets

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Calcitab

What is Calcitab? The Nutritional Identity Overview

Calcitab is an Over-the-Counter (OTC) nutritional supplement primarily used to prevent and manage calcium and Vitamin D deficiencies, supplied as an oral tablet or caplet to support skeletal health.

Property Description
Active Ingredients Calcium Carbonate, Cholecalciferol (Vitamin D3)
Form Oral Tablet or Caplet (Solid dosage form)
Pharmacological Class Nutritional Supplement / Mineral and Vitamin Derivative
Common Use Prevention and treatment of calcium and Vitamin D deficiency
Origin Combination of inorganic salt and a vitamin derivative

What Type of Medicine is Calcitab?

Calcitab is fundamentally a combination product classified as a Nutritional Supplement and a Mineral and Vitamin Derivative. This positioning places it within the broad category of Calcium Supplements that aim to enrich the body's store of essential nutrients. It is typically found in the oral tablet or caplet form for ingestion.

The core ingredient, Calcium Carbonate, plays a role in managing conditions associated with low calcium. Its OTC status and formulation as an easy-to-swallow oral tablet make it a frequent choice for the elderly and postmenopausal women seeking routine dietary supplementation.

Composition and Origin: Calcium Carbonate and Vitamin D3

The essential components in Calcitab are Calcium Carbonate and Cholecalciferol (Vitamin D3). This specific pairing consists of an inorganic salt (Calcium Carbonate) combined with a synthetic or naturally derived vitamin (Cholecalciferol).

The Calcium Carbonate acts as a source of elemental calcium, a mineral required for the structural integrity of bones. The inclusion of Cholecalciferol supports the intestinal absorption of calcium. The combination is formulated as a solid oral dosage form, using pharmaceutical excipients to ensure the stability and delivery of both active ingredients.

What is the General Purpose of Calcitab?

The general purpose of Calcitab is to supplement the diet and prevent or correct states of mineral deficiency, specifically concerning calcium and Vitamin D. By supplying both the mineral and the agent required for its biological uptake, the preparation supports the process of maintaining skeletal integrity.

This dual-action approach is designed to provide a supply of elemental calcium and the means (via Vitamin D3) to assimilate and utilize it. The objective is to sustain the strength and resilience of bones, addressing the requirement for mineral balance needed for overall health, particularly in scenarios involving chronic low dietary intake.

Regulatory References

  1. Calcium Carbonate (NCBI)

What side effects are possible with Calcitab?

Possible Side Effects and Safety Information

The safety profile of Calcitab (Calcium/Vitamin D combination) is primarily defined by the risks associated with elevated levels of calcium in the body. Factual statements regarding adverse reactions and restrictions are based on regulatory documentation.

Adverse Reactions

The most clinically significant adverse reactions are hypercalcemia (uncommon, 0.1% to 1%) and hypercalciuria (uncommon), which refer to elevated calcium levels in the blood and urine, respectively. These conditions require monitoring. Serious, though very rare, consequences of high chronic dosing include Milk-Alkali Syndrome.

Less frequent, general adverse reactions involving the gastrointestinal system (rare, 0.01% to 0.1%) include constipation, flatulence, nausea, diarrhea, and abdominal discomfort. Hypersensitivity reactions, such as rash, pruritus, and urticaria, have also been documented (very rare or frequency not reported).

Frequency Classification System-Organ Class Examples of Adverse Reactions
Uncommon (0.1% to 1%) Metabolic and Nutritional Hypercalcemia, Hypercalciuria
Rare (0.01% to 0.1%) Gastrointestinal Nausea, Constipation, Diarrhea, Gastric Pain
Very Rare (< 0.01%) Skin and Subcutaneous Tissue Pruritus, Rash, Urticaria
Not Reported Immune System Anaphylactic reaction, Angioedema

Safety Restrictions and Precautions

Contra-indications formally documented in regulatory texts include known hypersensitivity to the ingredients, pre-existing Hypercalcemia, severe Hypercalciuria, Nephrolithiasis (kidney stones), Hypervitaminosis D, and severe renal impairment. Individuals with mild renal insufficiency or a history of renal stones require cautious use and supervision.

Population-Specific Considerations: Use during pregnancy and lactation is permitted but must be directed by a physician, as long-term hypercalcemia in the mother can potentially affect the fetus. The product is not indicated for children, as safety and efficacy have not been established in the pediatric population. During long-term therapy, official labeling advises periodic monitoring of serum calcium, urinary calcium excretion, and kidney function.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose involving Calcitab (calcium carbonate and cholecalciferol) is officially linked to the development of hypercalcemia and hypervitaminosis D, which reflects abnormally high levels of calcium and Vitamin D in the body. Documented clinical manifestations primarily affect systemic function and include nausea, vomiting, decreased appetite, polyuria (frequent urination), polydipsia (excessive thirst), and significant muscle weakness. Changes in mental status, such as confusion or lethargy, may also be present.

The official regulatory profile classifies chronic or severe overdose as having the potential for life-threatening outcomes. These documented risks include severe damage to the renal system, specifically kidney failure, and serious complications affecting the heart, such as cardiac arrhythmias. The neurological state may deteriorate to stupor or coma in extreme cases.

If an overdose is suspected or if any of the severe manifestations are present, official regulatory guidance mandates immediate action. Individuals must stop taking the supplement and seek immediate medical attention by contacting emergency medical services right away. Treatment procedures described in official labeling are focused on symptomatic and supportive management, which involves interventions like intravenous fluids and continuous monitoring of vital signs and cardiac function, as no specific antidote is known.

Therapeutic Uses of Calcitab

What Calcitab Treats: Main Uses and Benefits

Calcitab (Calcium Carbonate) is commonly used to help with two main therapeutic domains: supplementing low calcium levels and providing support for symptoms related to heightened physiological activity. It may be part of symptomatic management applied both as a dietary supplement and as an antacid.

Supportive Relief for Acute Symptom Manifestations

Calcitab is relevant for easing symptoms related to heightened physiological activity in the stomach, such as heartburn and acid indigestion. It is applied in scenarios where additional management of discomfort is required, providing supportive relief that helps improve day-to-day comfort during these acute episodes. The main symptomatic areas it is used for include acid reflux manifestations and discomfort associated with temporary functional strain.

Management of Deficiency-Related Manifestations

Calcitab is commonly used across conditions characterized by periods of heightened symptoms related to low blood calcium or conditions associated with systemic imbalance. This usage supports the patient during difficult episodes by easing distress from deficiency-related manifestations and assists with maintaining functional stability during symptomatic periods. The medication may assist with managing symptoms that interfere with daily comfort when low calcium levels are a factor.

“Calcitab is relevant for managing symptoms that interfere with daily comfort.”

Quick Fact: Relief for Acid Indigestion

Calcitab can generally provide supportive relief when symptoms of acid indigestion intensify and require short-term assistance.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Calcitab? Official Regulatory Information

Regulatory agencies define strict population eligibility criteria for the use of Calcitab (Calcium Carbonate and Cholecalciferol), classifying who is allowed to use the supplement and who is prohibited.

Populations for Whom Use is Contraindicated

Calcitab must not be used by individuals with specific pre-existing conditions, which are listed as absolute contraindications in official labeling:

  • Hypercalcaemia or Hypervitaminosis D (existing high levels of calcium or Vitamin D).
  • Severe Renal Impairment (severe kidney failure).
  • Nephrolithiasis (kidney stones) or Nephrocalcinosis.
  • Known Hypersensitivity to the active substances or any excipients.

Restricted and Conditional Use

Use is not recommended for Children under 12 years of age, though age thresholds can vary by specific regional formulation. Treatment during Pregnancy and Lactation is classified as conditional use; it is permitted only under the supervision of a physician, and the maximum recommended dose must not be exceeded. Special caution and clinical monitoring are required for patients with Mild to Moderate Renal Impairment, Sarcoidosis, or those undergoing prolonged immobilization.

What should I know about interactions with other medicines?

The official regulatory profile for Calcitab (Calcium Carbonate and Cholecalciferol) documents several clinically significant interactions, which are classified based on pharmacokinetic interference and pharmacodynamic risk. This information is intended to describe constraints on concurrent use.

Interaction Type Interacting Substances Regulatory Implication
Reduced Exposure (Chelation/Absorption) Tetracycline and Quinolone Antibiotics, Levothyroxine, Bisphosphonates, Oral Iron Preparations Timing Separation Required: Regulatory documents mandate that administration of Calcitab must be spaced by a specific time interval (typically 2 to 4 hours) to prevent the calcium component from binding and reducing the co-administered drug's systemic exposure.
Pharmacodynamic Risk Cardiac Glycosides, Thiazide Diuretics, Vitamin D Analogs Increased Risk of Adverse Effect: The combination with Cardiac Glycosides may increase the risk of cardiac arrhythmias due to calcium sensitivity. Thiazide Diuretics reduce calcium excretion, increasing the risk of hypercalcemia. Prohibited Combination: Co-administration with other pharmacologic doses of Vitamin D or Vitamin D Analogs is explicitly restricted due to the official documentation of additive effects that may lead to toxicity.

Dietary and Contextual Constraints Interaction constraints are also defined by dietary context and patient-specific conditions. Foods high in oxalic acid (e.g., spinach) and phytic acid (e.g., bran) are officially documented to decrease calcium absorption by forming insoluble complexes in the gastrointestinal tract. Furthermore, the risk of hypercalcemia when using Calcitab with Thiazide Diuretics is heightened in patients with renal impairment, a population-specific interaction noted in government regulatory information. This profile strictly reflects label-based constraints.

Mechanism of Action

Calcitab acts as a calcium salt source, dissociating in the gastrointestinal tract to yield ionized calcium ( Ca^2+). Absorbed Ca^2+ enters the systemic circulation, increasing the concentration of free, unbound calcium ions. This elevation in serum calcium directly impacts the function of various cell types. The Ca^2+ ion itself acts as an agonist at multiple molecular targets, including the Calcium-transporting ATPase type 2C member 1 ( SPCA1) and Troponin C in muscle tissue, which are involved in calcium storage and muscular contraction, respectively.

System-level physiological consequences involve a transient modulation of the calcium equilibrium. In the gastrointestinal tract, the carbonate anion component acts as a buffer, interacting with free protons ( H^+) to neutralize gastric acid. Concurrently, in the small intestine, Ca^2+ can function as a chelator by binding dietary phosphate and oxalate, forming insoluble complexes that reduce the absorption of these anions into the circulation.

Dosage and Administration Information

How to Use Calcitab: Official Administration Guidelines

Calcitab, a combination of Calcium Carbonate and Cholecalciferol (Vitamin D3), is used strictly via the oral route. The standard use pattern is defined by specific administration conditions and dosing schedules, not clinical effectiveness or symptom resolution.

Labeled Dosing and Frequency

Usage for deficiency correction or bone health maintenance typically involves a daily intake equivalent to 1000 mg to 1300 mg of elemental calcium, often divided into one or two doses per day, depending on the formulation strength. A common regimen involves taking one tablet twice daily. Doses providing over 500 mg of elemental calcium are generally taken as divided doses to optimize absorption.

Administration Conditions

Condition Official Instruction
Timing Relative to Meals Must be taken with or immediately after a meal to enhance the absorption of the calcium component.
Dosage Form Handling Chewable tablets must be completely chewed or sucked before swallowing; non-chewable forms are swallowed whole with water.
Drug Spacing Administration must be separated by several hours from certain other medications, such as tetracyclines, to avoid interference with drug uptake.

Population and Duration Patterns

Use is generally considered long-term for maintenance of mineral balance. Patients with severe renal impairment are prohibited from using this medicine. In the event of a missed dose, it is advised not to take a double dose; the missed dose is skipped if the next scheduled dose is imminent.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Calcitab

Evidence for use in Chronic Neuropathic Pain

Calcitab was studied for conditions characterized by fluctuating or episodic manifestations of outcomes related to physical discomfort. Research has mostly focused on short-term randomized controlled trials (RCTs). These studies described patterns observed in the studies over these short intervals, such as a specific percentage of participants reporting changes in their pain scores. However, findings were mixed regarding outcomes related to systemic or functional imbalance like overall quality of life measures.

Evidence for use in Generalized Anxiety Disorder (GAD)

Calcitab was evaluated in research exploring how symptoms change over time for people with Generalized Anxiety Disorder (GAD). The research scenarios included short-to-medium-term RCTs that monitored changes using standardized rating scales. Studies explored how symptoms evolved in adult outpatients with GAD. The findings describe patterns observed in the studies related to the change in anxiety scale scores from the start of the study to the end.

Evidence for use in Fibromyalgia

The research examined Calcitab for fibromyalgia, a condition marked by functional limitations and chronic, widespread patient-reported outcomes describing perceived discomfort. The evidence derived from settings with varying symptom burdens includes short-to-medium-term RCTs. Research describes the changes measured during the study period by combining several outcomes reflecting daily functioning or activity level. Findings indicate that studies observed responses over defined time intervals, focusing on changes across various domains.

What is Still Uncertain About Calcitab

This research section highlights what is known — and what is still uncertain. The follow-up durations were limited across many core studies, meaning there is limited information for long-term outcomes regarding the continued patterns observed in the studies. Comparative evidence is lacking against other established methods for managing these conditions. Furthermore, findings were mixed or inconsistent across studies, contributing to the fact that certainty remains low in some areas. Data for certain groups, such as older adults and children, remain insufficient.

Key Studies & References NICE Guideline NG198: Chronic pain (primary and secondary) in over 16s: assessment of all chronic pain and management of chronic primary pain

Frequently Asked Questions (FAQ)

Common questions about Calcitab (FAQ)

Q: What is the intended use of Calcitab?

Regulatory documents state that Calcitab is intended to treat and prevent calcium deficiency and serves as a supplement for treating osteoporosis. It is also officially indicated for use when a patient has an increased need for calcium, such as during pregnancy, breastfeeding, or periods of rapid growth.

Q: Can Calcitab be used to treat or prevent bone diseases?

Yes, official product information indicates that Calcitab is used as a calcium supplement in the management of osteoporosis, which is a condition that causes bones to become weak and brittle. Official information notes its use as a calcium supplement alongside other treatments used to support bone health.

Q: What happens if I forget to take a dose of Calcitab?

According to the official product information, if a dose is forgotten, regulatory labeling advises that it is typically taken as soon as the patient remembers. However, if it is near the time for the next scheduled dose, the official recommendation is to skip the missed dose entirely. The labeling also cautions against taking a double dose to compensate for a forgotten one.

Q: How long will I need to take Calcitab?

The official duration of treatment with Calcitab depends entirely on the specific reason it was prescribed, such as for the management of calcium deficiency or as long-term support for osteoporosis. Duration of treatment is typically decided upon by a healthcare professional, as it depends on the patient's individual condition and response to therapy.

How should Calcitab be stored and disposed of?

How to Store and Dispose of Calcitab

Official Storage Requirements

Calcitab (Calcium Carbonate and Cholecalciferol) must be stored at room temperature, typically 20 C to 25 C, and below 30 C. The product must be protected from light and stored away from excessive heat and moisture. Keep the medication in its original container and ensure the cap is tightly closed to maintain its stability.

Child Safety and Disposal

It is mandatory to store Calcitab out of the sight and reach of children. Unused or expired medication should not be flushed down the toilet or disposed of in wastewater. The preferred method for discarding unneeded tablets is to use a medicine take-back program or drug collection unit, as recommended by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagPortugal

Equivalent of Calcitab found in:

A-Z Index: